Regeneron Pharmaceuticals (NASDAQ:REGN) is one of the leaders in the ophthalmic disease therapeutics market. In this article, dear Seeking Alpha readers, I present five factors that explain why I ...

Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.

On February 18, 2025, in United States v. Regeneron Pharmaceuticals, the First Circuit held that to establish civil liability under the False ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Long Island's six Regeneron Science Talent Search finalists are not yet out of high school and already, they've worked in some of the country's leading laboratories, helped to advance scientific ...

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and commercialise drugs targeting eye, central nervous system (CNS ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for Dupixent to treat adults with bullous pemphigoid. The ...